AL0804
Neuronopathic Gaucher disease (Types II/III); GM1/GM2 Gangliosidosis; Genetic Parkinson's
PreclinicalActive
Key Facts
Indication
Neuronopathic Gaucher disease (Types II/III); GM1/GM2 Gangliosidosis; Genetic Parkinson's
Phase
Preclinical
Status
Active
Company
About AceLink Therapeutics
AceLink Therapeutics is a private, clinical-stage biotech founded in 2018 and headquartered in Newark, California, with a significant operational presence in Shanghai, China. The company's core strategy is targeting glycolipid biology with small molecule inhibitors and activators to treat rare genetic diseases, with three lead programs in Phase 2 and preclinical development. Its most advanced asset, AL01211, is a non-brain penetrant GCS inhibitor in Phase 2 for Fabry disease and Type I Gaucher disease, positioning it in a competitive but high-need therapeutic area.
View full company profile